Evidence map›Paper›PMID 41768859›Full record

ArticleEXCLI journal2026

Candesartan cilexetil as a repurposed therapeutic candidate for nasopharyngeal carcinoma: Integrated in vitro and in silico analyses.

Chawalit Ngernsombat, Utid Suriya, Somsiri Udompaisarn, Natta Panomchoeng, Tavan Janvilisri

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in EXCLI journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Chawalit NgernsombatDivision of Biochemistry, Department of Preclinical Science, Faculty of Medicine, Thammasat University, Pathumthani 12120, Thailand.
Utid SuriyaDepartment of Biochemistry, Faculty of Science, Mahidol University, Bangkok 10400, Thailand.
Somsiri UdompaisarnDepartment of Microbiology, Faculty of Science, Chulalongkorn University, Bangkok 10330, Thailand.
Natta PanomchoengDepartment of Biochemistry, Faculty of Science, Mahidol University, Bangkok 10400, Thailand.
Tavan JanvilisriDepartment of Microbiology, Faculty of Science, Chulalongkorn University, Bangkok 10330, Thailand.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Nasopharyngeal carcinoma (NPC) is prevalent in East and Southeast Asia and is often diagnosed at advanced stages, where current treatment options are limited and associated with high relapse rates and toxicity. Repurposing clinically approved drugs provides a rapid, cost-effective strategy to identify new therapeutic interventions. Here, we investigated candesartan cilexetil (CC), an angiotensin II type 1 receptor (AT1R) blocker widely used for hypertension (13), for its potential anti-cancer effects in NPC.

Indexed as

angiotensin II type 1 receptorcandesartan cilexetildrug repurposingMAPK signalingmolecular dynamics simulationnasopharyngeal carcinoma

Identifiers

PMID41768859
PMCPMC12946440

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.